09.09.2014 14:30:00
|
ReproCELL Acquires the iPS Cell Business Unit of Stemgent, Inc.
ReproCELL (JASDAQ:4978) announced that it will acquire the iPS Cell Business Unit of Stemgent, Inc. This acquisition allows the ReproCELL Group to expand the product lineups of its iPS Cell Business and establish technical advantages, promoting great differentiation.
Stemgent has succeeded in launching many worldwide leading iPS cell research reagent products including mRNA reprogramming kit, xeno-free culture media, and specialty chemicals for cell differentiation, and has established a world-famous, proven and trusted brand in the iPS cell field. Through the acquisition, ReproCELL Group can offer a wide variety of products with full coverage of iPS cell technologies, while also strengthening its sales channel and marketing function in the United States. In addition, the iPS Cell Business Unit of Stemgent has a broad network of academic researchers including a strong scientific advisory board in the United States, while ReproCELL has a wide academic network in Japan with a strong scientific advisory board, as well as its founder Prof. Nakatsuji at Kyoto University and Prof. Nakauchi at the University of Tokyo. The strongest academic network combined in United States and Japan will give us sustainable technical advantages in the iPS cell field.
(Reference)
ReproCELL Incorporated
ReproCELL was
established as a venture company originating from the University of
Tokyo and Kyoto University and has been the pioneer in the iPS cell
business, succeeding in the commercialization of the world's first human
iPS cell products in 2009 and with the world's most advanced research
and technology. In addition, through the recent acquisitions of
Reinnervate (UK) and BioServe (US), ReproCELL is proceeding towards the
establishment of a global distribution network, and technology synergy
and new product introductions.
Stemgent, Inc.
Stemgent is engaged in working alongside some
of the world’s leading iPS cell scientists in developing innovative
technology and application solutions for the advancement of iPS cell
research. Its mission is to help simplify and support cellular
reprogramming research by producing products being designed by leading
iPS cell researchers worldwide.
(URL)
ReproCELL: https://www.reprocell.com/en/
Reinnervate:
http://reinnervate.com/
BioServe:
http://www.bioserve.com/
Stemgent:
https://www.stemgent.com/
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu ReproCELL Incorpmehr Nachrichten
Keine Nachrichten verfügbar. |